Company news
Matinas Biopharma Holdings, Inc. (AMEX:MTNB) news
Matinas Biopharma Holdings, Inc. news releases on 6ix. Latest, Sep 4, 2026: Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued…
Press releases & updates
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
September 4, 2026
Matinas BioPharma : Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals
July 13, 2026
Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals
July 13, 2026
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance
June 26, 2026
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
April 3, 2026
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
March 11, 2025
Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors
February 13, 2025
Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair
February 7, 2025
Matinas BioPharma Receives NYSE Noncompliance Notice
January 10, 2025
Matinas BioPharma : Current Report Form 8 K
November 27, 2024
Matinas BioPharma : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)
November 13, 2024
Matinas BioPharma : Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction Form 8 K
October 31, 2024
Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
August 14, 2024
Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024
August 7, 2024
Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program
June 24, 2024
New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
May 16, 2024
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
May 9, 2024
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024
May 2, 2024
Matinas BioPharma Prices $10 Million Registered Direct Offering
April 3, 2024